INAB
USDIN8bio Inc. Common Stock
$2.180+0.060 (2.830%)
Real-time Price
Healthcare
Biotechnology
United States
Price Chart
Loading Chart...
Key Metrics
Market Metrics
Open
$2.120
High
$2.300
Low
$2.120
Volume
0.13M
Company Fundamentals
Market Cap
7.5M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.17M
Exchange
NCM
Currency
USD
52-Week Range
Low $2.05Current $2.180High $27.3
Related News
GlobeNewswire
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that
View more
GlobeNewswire
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is
View more
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.